[Psychotic disorders in Parkinson disease: value of clozapine]. 1994

P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau

UI MeSH Term Description Entries
D008297 Male Males
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
November 1997, Presse medicale (Paris, France : 1983),
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
January 2010, Clinical neuropharmacology,
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
January 2004, Revista de neurologia,
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
January 2012, Clinical neuropharmacology,
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
September 2015, The Cochrane database of systematic reviews,
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
December 1996, Neurology,
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
April 2024, The Journal of clinical psychiatry,
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
June 1994, The Journal of clinical psychiatry,
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
October 1994, Lancet (London, England),
P Courtet, and M Abbar, and J Monié, and G Amphoux, and D Castelnau
November 2017, The mental health clinician,
Copied contents to your clipboard!